与阿托皮性皮肤炎中杜皮卢马布反应相关的因素:系统性审查和元分析
Piyaporn Chokevittaya1, Noraworn Jirattikanwong2, Torpong Thongngarm1
1Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
The journal of allergy and clinical immunology. In practice
|September 12, 2024
概括
某些患者特征,包括女性性别,年龄较小,没有过敏性鼻炎,BMI较低,和低乙氨基酸细胞数量,预测对阿托皮性皮炎 (AD) 的杜皮卢马布的反应更好. 这些因素有助于艾滋病患者的治疗决策.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 杜皮卢马布已批准用于中度至重度的亚托皮性皮肤炎 (AD).
- 一部分患者对dupilumab的反应有限.
- 在阿尔茨海默病中影响dupilumab反应的因素尚未得到充分确定.
研究的目的:
- 系统地审查和识别与阿兹海默症患者杜皮卢马布反应相关的因素.
- 综合治疗成功预测因素的证据.
主要方法:
- 在主要数据库 (PubMed,MEDLINE,Embase,Ovid,Cochrane) 进行了全面的文献搜索,截至2023年3月.
- 随机效应模型的元分析被用于合成因子的概率比率和95%置信区间,这些因素与12-16周 75%的湿疹区域和严重性指数 (EASI) 降低相关.
- 主要结局是确定与AD中dupilumab反应相关的因素.
主要成果:
- 对21项研究 (5,575名患者) 的分析揭示了与有利的杜比卢马布反应 (EASI75) 相关的因素:女性性别 (OR 2.16),年轻年龄 (OR 2.81),没有过敏性鼻炎 (OR 2.64),低体重指数 (OR 1.97) 和低血中异敏细胞计数 (OR 6.47).
- 这些因素的证据确定性非常低.
- 在dupilumab反应和发病时的年龄,基线EASI得分,总IgE或血清乳酸脱酶水平之间没有发现任何关联.
结论:
- 女性性别,年龄较小,没有过敏性鼻炎,低BMI和血中低氨基酸细胞数量与AD.在AD中有利的dupilumab反应有关.
- 在临床实践中,在处方dupilumab时应考虑这些预测因素.
- 由于证据的确定性非常低,可能需要进一步的研究来证实这些发现.
相关概念视频
01:27Allergic Drug Reactions
821
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
821
01:17Drugs Used in Lower Respiratory Disorders: Overview
362
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
362
02:06Allergic Reactions
27.3K
Overview
27.3K
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
246
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
246